Insider Selling: Quantum-Si (NASDAQ:QSI) CFO Sells $11,042.56 in Stock

by · The Cerbat Gem

Quantum-Si Incorporated (NASDAQ:QSI – Get Free Report) CFO Jeffry Keyes sold 8,627 shares of Quantum-Si stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $1.28, for a total value of $11,042.56. Following the completion of the transaction, the chief financial officer owned 1,163,197 shares of the company’s stock, valued at approximately $1,488,892.16. This trade represents a 0.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Quantum-Si Price Performance

NASDAQ:QSI remained flat at $1.27 during mid-day trading on Monday. 5,071,186 shares of the company traded hands, compared to its average volume of 3,958,795. Quantum-Si Incorporated has a 52-week low of $0.95 and a 52-week high of $5.77. The firm’s fifty day simple moving average is $1.66 and its 200-day simple moving average is $1.58. The company has a market capitalization of $273.67 million, a P/E ratio of -1.90 and a beta of 2.97.

Quantum-Si (NASDAQ:QSI – Get Free Report) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.17) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.17). The business had revenue of $0.55 million during the quarter, compared to analysts’ expectations of $0.60 million. Quantum-Si had a negative net margin of 3,677.97% and a negative return on equity of 47.90%. As a group, equities analysts anticipate that Quantum-Si Incorporated will post -0.65 EPS for the current fiscal year.

Analyst Ratings Changes

QSI has been the topic of several research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Quantum-Si in a report on Monday, December 8th. Canaccord Genuity Group decreased their price target on shares of Quantum-Si from $2.00 to $1.50 and set a “hold” rating for the company in a research note on Monday. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Quantum-Si presently has an average rating of “Hold” and a consensus target price of $3.60.

Read Our Latest Stock Analysis on QSI

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Prudential Financial Inc. purchased a new stake in Quantum-Si in the 2nd quarter valued at approximately $25,000. JTC Employer Solutions Trustee Ltd acquired a new position in Quantum-Si during the second quarter worth $26,000. Cerity Partners LLC purchased a new position in Quantum-Si in the second quarter worth $29,000. Wolverine Asset Management LLC lifted its holdings in Quantum-Si by 140.0% in the second quarter. Wolverine Asset Management LLC now owns 16,501 shares of the company’s stock valued at $32,000 after acquiring an additional 9,626 shares during the period. Finally, Capital Investment Advisory Services LLC boosted its position in shares of Quantum-Si by 100.0% during the 3rd quarter. Capital Investment Advisory Services LLC now owns 20,000 shares of the company’s stock worth $28,000 after purchasing an additional 10,000 shares in the last quarter. 39.90% of the stock is currently owned by institutional investors and hedge funds.

Quantum-Si Company Profile

(Get Free Report)

Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company’s core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods.

Quantum-Si’s product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software.

Further Reading